Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00404170 · ClinicalTrials.gov registry record · Phase 2
Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease
A Phase 2 study, sponsored by Institute for Neurodegenerative Disorders.
- Completed
- Registry status
- Phase 2
- Development phase
- 396
- Enrollment target
NCT00404170 is a Phase 2 study that has completed, run by Institute for Neurodegenerative Disorders. The registered enrollment target is 396 participants.
The verdict
NCT00404170, a Phase 2 study, has completed, sponsored by Institute for Neurodegenerative Disorders.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 396 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the utility of dopamine transporter imaging in monitoring and predicting the progression of Parkinson disease. This study will be performed in the PRECEPT cohort, an already existing cohort of 806 subjects recruited to participate in the study called, A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Assess the Efficacy and Safety of CEP-1347 in Patients With Early Parkinson's Disease - (PRECEPT), sponsored by Cephalon and Lundbeck and coordinated by the Parkinson Study Group. The imaging data from this long-term PRECEPT follow-up study will allow us to evaluate the long-term progression of DAT loss in PD, the long-term follow-up of SWEDD subjects, the relationship between long-term clinical and imaging PD outcomes, and the relationship between long-term imaging outcomes and genetic and biochemical biomarkers of PD progression.
Interventions
- DRUG B-CIT and SPECT imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 396 participants |
| Start Date | 2006-11 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00404170
The ClinicalTrials.gov registry entry for NCT00404170 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 396 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Institute for Neurodegenerative Disorders, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which B-CIT and SPECT imaging is the first listed.
NCT00404170 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00404170 about?
NCT00404170 is a clinical study titled "Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease". The purpose of this study is to investigate the utility of dopamine transporter imaging in monitoring and predicting the progression of Parkinson disease. This study will be performed in the PRECEPT cohort, an already existing cohort of 806 subjects recruited to participate in the study called, A Ra...
What is the current status of trial NCT00404170?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 396 participants. The study started on 2006-11. Estimated completion is 2014-07.
What interventions are being tested in trial NCT00404170?
The interventions under investigation include: B-CIT and SPECT imaging (DRUG).
Who is sponsoring clinical trial NCT00404170?
This trial is sponsored by Institute for Neurodegenerative Disorders, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.